Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNFRSF1A | P19438 | 7/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | PGK1 | P00558 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17167476 | 0.81 | APP (0.59) | TNFRSF1AERN1FYNS1PR1 | |
| SCHEMBL14093047 | 0.78 | TNFRSF1A (0.47) | TNFRSF1AERN1FYNS1PR1HDAC6 | |
| SCHEMBL8940769 | 0.75 | HTR7 (0.53) | HTR7 | |
| SCHEMBL13766429 | 0.74 | APP (0.62) | ERN1PTGDRCYP1A2CYP2A6 | |
| SCHEMBL758403 | 0.74 | TNFRSF1A (0.43) | TNFRSF1AERN1FYNS1PR1HDAC6 | |
| SCHEMBL5990688 | 0.74 | ERN1 (0.47) | TNFRSF1AERN1HTR7 | |
| SCHEMBL5990023 | 0.73 | NAMPT (0.55) | NAMPTHDAC6CLK1DYRK1A | |
| SCHEMBL6054895 | 0.72 | HTR7 (0.50) | PGK1HTR7CYP1A2CYP2A6 | |
| SCHEMBL31402836 | 0.72 | CYP1A1 (0.49) | TNFRSF1AERN1FYNCYP1A2CYP2A6 | |
| SCHEMBL5991474 | 0.72 | HTR7 (0.49) | HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417053-B2 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAP4K2, MAPKAPK5 | TNFRSF1A 2807/4885ERN1 1066/4885PGK1 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.